Piramal Life Sciences Limited (PLSL) is an independent research driven drug company that was recently demerged from Piramal Healthcare Limited (Formerly know as Nicholas Piramal India Limited). PLSL was formerly the NCE R&D division of NPIL. PLSL has state-of-the-art R&D laboratories built over 200,000 square-feet of space in Mumbai, India and over 300 scientists engaged in drug discovery and development.
Latest News Updates
- Piramal Life Sciences Commences Phase I Trial on New Molecule for Diabetes - Metabolic Syndrome in Canada
- Piramal Life Sciences receives DCGI Approval to conduct two Phase I/II Combination Trials of P276 for Pancreatic, and Head and Neck Cancer in India
- Piramal Life Sciences begins Phase II trial of P276 for Mantle Cell Lymphoma
- More News
Upcoming R&D Events
The vision behind the newly built Nicholas Piramal Research Centre was to establish a world-class R&D program that would provide opportunities for young scientists in India
